PDF(Pubmed)
Abstract：
OBJECTIVE: The purpose of this clinical study was to evaluate the efficacy and safety of intraoperative chemotherapy (IOC) with intraoperative intraperitoneal implantation of 5-fluorouracil (5-FU) in colorectal cancer (CRC) patients.
METHODS: In this study, 165 patients who underwent colorectal radical surgery were selected, of whom 111 in the experimental group received surgical treatment with an intraperitoneal 5-fluorouracil (5-FU) implantation. Fifty-four patients who did not undergo intraperitoneal implantation of 5-FU were matched to compare the progression-free survival (PFS) and overall survival (OS) with the former.
RESULTS: We also studied the differences in the changes of different biochemical indicators between the two groups before and after surgery, and there were significant differences in leukocytes, neutrophils, and lymphocytes before and after (P < 0.05), while for sodium ions, potassium ions, platelets, alanine transaminase, aspartate transaminase, creatinine, urea, and albumin, there were no significant differences. This may be related to the intraperitoneal chemotherapy implant entering the blood circulation. For 5-year OS, there were 85/111 (76.58%) in the 5-FU group (P = 0.013) and 35/54 (64.81%) in the control group; for 5-year PFS, there were 84/111 (75.68%) in the 5-FU group and 29/54 (53.70%) in the control group (P = 0.02). All the experimental groups were better than the control group with a significant difference in the experimental results.
CONCLUSIONS: For CRC surgery patients, intraperitoneal implantation of slow-release 5-FU drugs, which is a safe and simple procedure, can improve the prognosis of the patients.
BACKGROUND: No clinical trials were performed in the study.
METHODS: In this study, 165 patients who underwent colorectal radical surgery were selected, of whom 111 in the experimental group received surgical treatment with an intraperitoneal 5-fluorouracil (5-FU) implantation. Fifty-four patients who did not undergo intraperitoneal implantation of 5-FU were matched to compare the progression-free survival (PFS) and overall survival (OS) with the former.
RESULTS: We also studied the differences in the changes of different biochemical indicators between the two groups before and after surgery, and there were significant differences in leukocytes, neutrophils, and lymphocytes before and after (P < 0.05), while for sodium ions, potassium ions, platelets, alanine transaminase, aspartate transaminase, creatinine, urea, and albumin, there were no significant differences. This may be related to the intraperitoneal chemotherapy implant entering the blood circulation. For 5-year OS, there were 85/111 (76.58%) in the 5-FU group (P = 0.013) and 35/54 (64.81%) in the control group; for 5-year PFS, there were 84/111 (75.68%) in the 5-FU group and 29/54 (53.70%) in the control group (P = 0.02). All the experimental groups were better than the control group with a significant difference in the experimental results.
CONCLUSIONS: For CRC surgery patients, intraperitoneal implantation of slow-release 5-FU drugs, which is a safe and simple procedure, can improve the prognosis of the patients.
BACKGROUND: No clinical trials were performed in the study.
摘要：
目的：本临床研究的目的是评估结直肠癌（CRC）患者术中化疗（IOC）联合术中腹腔植入5-氟尿嘧啶（5-FU）的疗效和安全性。
方法：在本研究中，选择165例接受结直肠根治术的患者,实验组中的111人接受了腹膜内5-氟尿嘧啶（5-FU）植入的手术治疗。对54例未进行5-FU腹膜内植入的患者进行匹配，以比较前者的无进展生存期（PFS）和总生存期（OS）。
结果：我们还研究了两组手术前后不同生化指标变化的差异，白细胞有显著差异，中性粒细胞，前后淋巴细胞（P<0.05），而对于钠离子，钾离子，血小板,丙氨酸转氨酶，天冬氨酸转氨酶,肌酐,尿素,和白蛋白,没有显著差异。这可能与腹膜内化疗植入物进入血液循环有关。对于5年操作系统，5-FU组85/111(76.58%)(P=0.013),对照组35/54(64.81%);5年PFS,5-FU组84/111（75.68％），对照组29/54（53.70％）（P=0.02）。各实验组均优于对照组,实验结果差异有统计学意义。
结论：对于CRC手术患者，腹腔植入缓释5-FU药物，这是一个安全而简单的程序，可以改善患者的预后。
背景：本研究未进行临床试验。
方法：在本研究中，选择165例接受结直肠根治术的患者,实验组中的111人接受了腹膜内5-氟尿嘧啶（5-FU）植入的手术治疗。对54例未进行5-FU腹膜内植入的患者进行匹配，以比较前者的无进展生存期（PFS）和总生存期（OS）。
结果：我们还研究了两组手术前后不同生化指标变化的差异，白细胞有显著差异，中性粒细胞，前后淋巴细胞（P<0.05），而对于钠离子，钾离子，血小板,丙氨酸转氨酶，天冬氨酸转氨酶,肌酐,尿素,和白蛋白,没有显著差异。这可能与腹膜内化疗植入物进入血液循环有关。对于5年操作系统，5-FU组85/111(76.58%)(P=0.013),对照组35/54(64.81%);5年PFS,5-FU组84/111（75.68％），对照组29/54（53.70％）（P=0.02）。各实验组均优于对照组,实验结果差异有统计学意义。
结论：对于CRC手术患者，腹腔植入缓释5-FU药物，这是一个安全而简单的程序，可以改善患者的预后。
背景：本研究未进行临床试验。
